(Q54487286)

30 May 2018

title

A human papillomavirus type 16 vaccine by oral delivery of L1 protein. (English)

1 reference

30 May 2018

8

Hideyo Yasuda

1 reference

30 May 2018

author name string

Toshiyuki Sasagawa

1

1 reference

30 May 2018

Mayuko Tani

2

1 reference

30 May 2018

Walid Basha

3

1 reference

30 May 2018

Robert C Rose

4

1 reference

30 May 2018

Hideki Tohda

5

1 reference

30 May 2018

Yuko Giga-Hama

6

1 reference

30 May 2018

Khadijeh K Azar

7

1 reference

30 May 2018

Akemi Sakai

9

1 reference

30 May 2018

Masaki Inoue

10

1 reference

30 May 2018

publication date

1 June 2005

1 reference

30 May 2018

published in

Virus Research

1 reference

30 May 2018

volume

110

1 reference

30 May 2018

issue

1-2

1 reference

30 May 2018

page(s)

81-90

1 reference

30 May 2018

Abrogation of oral tolerance by feeding encapsulated antigen

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.02.001

Production of human papillomavirus type 16 virus-like particles in transgenic plants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.02.001

Epidemiology of Acquisition and Clearance of Cervical Human Papillomavirus Infection in Women from a High‐Risk Area for Cervical Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.02.001

Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.02.001

A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.02.001

Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM, and mucosal IgA antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.02.001

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.02.001

Natural history of cervicovaginal papillomavirus infection in young women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.02.001

Enhanced immunogenicity of human papillomavirus 16 L1 genetic vaccines fused to an ER-targeting secretory signal peptide and RANTES.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.02.001

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.02.001

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.02.001

Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.02.001

Epidemiologic classification of human papillomavirus types associated with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.02.001

Cancer burden in the year 2000. The global picture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.02.001

Sequence variation in the capsid protein genes of human papillomavirus type 16

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.02.001

Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.02.001

Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.02.001

Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.02.001

Immune evasion in human papillomavirus-associated cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.02.001

A copy-number-controlled expression vector for the fission yeast Schizosaccharomyces pombe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.02.001

Oral immunogenicity of human papillomavirus-like particles expressed in potato

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.02.001

Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.02.001

Human papillomaviruses in the pathogenesis of anogenital cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.02.001

Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.02.001

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIRUSRES.2005.02.001

1 reference

30 May 2018

1 reference

30 May 2018